Related Experiment Videos
[Brucella vaccination in professionally exposed subjects. Prospective study].
A Strady1, M Lienard, J C Gillant
1Service des Maladies infectieuses, Hôpital Robert-Debré, Reims.
Presse Medicale (Paris, France : 1983)
|September 19, 1992
Summary
This study evaluated a Brucella abortus biotype 1 (B19 strain) vaccine in 161 subjects. The vaccine showed good seropositivity and safety, but clinical effectiveness requires further investigation.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Brucella infections pose a significant risk to individuals with occupational exposure.
- A vaccine derived from the phenol-insoluble fraction of Brucella abortus biotype 1 (B19 strain) was developed.
Purpose of the Study:
- To assess the safety and immunogenicity of the B19 strain vaccine in a prospective phase IV study.
- To evaluate the response to primary vaccination and booster injections.
Main Methods:
- A cohort of 303 professionally exposed subjects was enrolled.
- 161 subjects received the B19 vaccine, with booster injections at 18 and 36 months.
- Local reactions, systemic reactions, and seropositivity rates were monitored.
Main Results:
- 88.5% of eligible subjects accepted vaccination.
- Seropositivity reached 80% after primary vaccination.
- Local pain (45.2%) and moderate systemic reactions (5%) were reported; no detectable hypersensitivity was observed.
Conclusions:
- The B19 vaccine demonstrates good immunogenicity and a favorable safety profile.
- Booster injections maintained seropositivity.
- Further comparative studies are needed to accurately evaluate clinical effectiveness and rule out subclinical infections.